Jung Woo Han, Christopher Seungkyu Lee, Seung Min Hahn, Won Kee Ahn, Hyo Sun Kim, Hyeseon Yun, Sung Chul Lee, Byung Moon Kim, Dong Joon Kim, Chuhl Joo Lyu
Cancer Res Treat. 2023;55(1):270-278. Published online May 24, 2022
Purpose The advances in the treatment of retinoblastoma have enabled salvaging the globe in advanced stages with intra-arterial chemotherapy (IAC). We developed a strategy of alternate application of systemic intravenous chemotherapy (IVC) and IAC (referred to as alternate systemic IVC and IAC; ASIAC) to reduce central nervous metastases during IAC and examined its efficacy and safety in eye globe salvage in this study.
Materials and Methods Between January 2010 and February 2021, 43 eyes of 40 patients received ASIAC treatment for retinoblastoma at the Yonsei Cancer Center, Yonsei University Health System. Their medical records were reviewed retrospectively to evaluate the eye salvage rate (ESR), defined from diagnosis to enucleation. High-risk retinoblastoma was defined as group D or E by the International Classification of Retinoblastoma.
Results The study enrolled 38 and five cases of high-risk and low-risk retinoblastoma, respectively. In total, 178 IAC and 410 IVC courses were administered, with a median of 4 (interquartile range [IQR], 3.0 to 5.0) IAC and 9 (IQR, 6.0 to 11) IVC courses per eye, respectively. The 5-year ESR was 60.4%±8.7% for the whole cohort, 100% for low-risk retinoblastoma, and 53.6%±9.8% for high-risk retinoblastoma. Among those diagnosed since 2015, the 5-year ESR for high-risk retinoblastoma was 63.5%±14.0%. Fifteen eyes underwent enucleation; no viable tumor was found in three enucleated eyes. There were no deaths in this cohort.
Conclusion Primary IAC-IVC (i.e., ASIAC) for patients with retinoblastoma was tolerable and effective in salvaging the eye and maintaining survival.
Citations
Citations to this article as recorded by
Selective ophthalmic arterial injection using a balloon catheter for retinoblastoma: a seven-year clinical evaluation Sota Oguro, Yi Ning Chen, Takashi Yamane, Makoto Mohri, Shigenobu Suzuki Japanese Journal of Ophthalmology.2024; 68(4): 346. CrossRef
Hematological Second Primary Malignancy in Pediatric Retinoblastoma: A Case Report and Systematic Review Seung Hyun Park, Hyun Young Park, Heejin Kim, Jung Woo Han, Jin Sook Yoon Ophthalmic Plastic & Reconstructive Surgery.2024; 40(5): 487. CrossRef
Purpose
Uveal melanoma has a very poor prognosis despite successful local primary tumor treatment. In this study, we investigated prognostic factors that more accurately reflected the likelihood ofrecurrence and survival and delineated a prognostic model that could effectively identify different risk groups based on initial clinical parameters.
Materials and Methods
Prognostic factors associated with distant recurrence, recurrence-free survival (RFS), progression-free survival, and overall survival from distant recurrence to death (OS2) were analyzed in 226 patients with stage I-III uveal melanoma who underwent primary local therapy.
Results
Forty-nine patients (21.7%) had distant recurrences, which occurred most frequently in the liver (87.7%). In a multivariate analysis, local radiotherapy improved RFS among patients with multiple recurrence risk factors relative to excision (not reached vs. 19.0 months, p=0.004). Patients with BRCA1-associated protein-1 (BAP1)‒negative primary tumors showed a longer RFS duration after primary treatments, while those with BAP1-negative metastatic tissues had a shorter OS2 compared to those with BAP1-positive tumors, both not statistically insignificance (RFS: not reached vs. 82.0 months, p=0.258; OS2: 15.7 vs. 24.4 months, p=0.216). Male sex (hazard ratio [HR], 3.79; p=0.012), a short RFS (HR, 4.89; p=0.014), and a largest metastatic tumor linear diameter ≥ 45 mm (HR, 5.48; p=0.017) were found to correlate with worse post-recurrence survival.
Conclusion
Risk factors could be used to classify uveal melanoma cases and subsequently direct individual treatment strategies. Furthermore, metastasectomy appears to contribute to improved survival outcomes.
Citations
Citations to this article as recorded by
Favorable Outcomes of Patients With High-Risk Uveal Melanoma Treated With a Novel Linear Accelerator-Based Frameless Fractionated Stereotactic Radiosurgery Louis Cappelli, Mehak M. Khan, Carol L. Shields, Sara E. Lally, Muhammad Sharif, Haisong Liu, Yingxuan Chen, Jade Park, Tingting Zhan, Wenyin Shi American Journal of Ophthalmology.2025; 271: 417. CrossRef
Uveal Melanoma: Comprehensive Review of Its Pathophysiology, Diagnosis, Treatment, and Future Perspectives Merve Kulbay, Emily Marcotte, Raheem Remtulla, Tsz Hin Alexander Lau, Manuel Paez-Escamilla, Kevin Y. Wu, Miguel N. Burnier Biomedicines.2024; 12(8): 1758. CrossRef
Impact of Metastatic Pattern on Survival in Patients with Posterior Uveal Melanoma: A Retrospective Cohort Study Tine G. Hindso, Peter S. Jensen, Mette B. Sjøl, Kristoffer Nissen, Camilla W. Bjerrum, Eric von Benzon, Carsten Faber, Steen F. Urbak, Marco Donia, Inge M. Svane, Eva Ellebaek, Steffen Heegaard, Karine Madsen, Jens F. Kiilgaard Cancers.2024; 16(19): 3346. CrossRef
Identification of a prognostic six-immune-gene signature and a nomogram model for uveal melanoma Binghua Yang, Yuxia Fan, Renlong Liang, Yi Wu, Aiping Gu BMC Ophthalmology.2023;[Epub] CrossRef
Prognostic Value of the Radiomics-Based Model in the Disease-Free Survival of Pretreatment Uveal Melanoma: An Initial Result Yaping Su, Xiaolin Xu, Fang Wang, Panli Zuo, Qinghua Chen, Wenbin Wei, Junfang Xian Journal of Computer Assisted Tomography.2023; 47(1): 151. CrossRef
Uveal melanoma pathobiology: Metastasis to the liver Prisca Bustamante, Léo Piquet, Solange Landreville, Julia V. Burnier Seminars in Cancer Biology.2021; 71: 65. CrossRef
Malignant uveal melanoma with metastatic recurrence to the pancreas: A case report Wei‐Chun Weng, Tzung‐Jiun Tsai, Wen‐Chi Chen, Jin‐Shiung Cheng, Wei‐Chih Sun Advances in Digestive Medicine.2021; 8(3): 178. CrossRef
Role of somatic mutations and chromosomal aberrations in the prognosis of uveal melanoma in a Spanish patient cohort Paula Silva‐Rodríguez, Manuel Bande, Daniel Fernández‐Díaz, Nerea Lago‐Baameiro, María Pardo, María José Blanco‐Teijeiro, Fernando Domínguez, Lourdes Loidi, Antonio Piñeiro Acta Ophthalmologica.2021;[Epub] CrossRef
Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort Laura Ling Ying Tan, Jiancheng Hong, Wei Lin Goh, Esther Wei Yin Chang, Valerie Shiwen Yang, Eileen Poon, Nagavalli Somasundaram, Mohamad Farid, Anita Sook Yee Chan, Jason Yongsheng Chan Scientific Reports.2020;[Epub] CrossRef
ЕФЕКТИВНІСТЬ РАДІОХВИЛЬОВОЇ (3,8 МГЦ) БЛОКЕКСЦИЗІЇ МЕЛАНОМИ ЦИЛІОХОРІОЇДАЛЬНОЇ ЛОКАЛІЗАЦІЇ O. V. Khomyakova Здобутки клінічної і експериментальної медицини.2020; (3): 173. CrossRef
Purpose
The purpose of this study was to report clinical outcomes of ruthenium-106 (106Ru) brachytherapy with or without additional local therapy for choroidal melanomas in Korean patients.
Materials and Methods
A total of 88 patients diagnosed with choroidal melanomas were treated with 106Ru brachytherapy between 2006 and 2012. Patients were divided into two groups according to their tumor height: a large group (≥ 6 mm, n=50) and a small group (< 6 mm, n=38). Most patients in the large group received combined therapy with local excision and/or transpupillary thermotherapy. In general, 85-95 Gy was administered to the apex of the tumor, while 100 Gy was administered to the point 2-6 mm from the outer surface of the sclera for patients undergoing combined therapy.
Results
The median follow-up duration was 30 months. The 3-year local control rate was significantly higher in the small group than in the large group (94% vs. 70%, p=0.047). The free from distant metastasis (FFDM) rate and the overall survival (OS) rate were also higher in patients in the small group (3-year FFDM, 97% vs. 76%; p=0.031 and 3-year OS, 97% vs. 72%; p=0.036). A total of 13 patients underwent enucleation. The eye-preservation rate was also higher in the small group (3-year eye-preservation rate, 94% vs. 70%; p=0.050), and tumor height was a significant prognostic factor for eye-preservation.
Conclusion 106Ru brachytherapy showed favorable outcomes in small choroidal melanomas in Korean patients. Although additional local treatment could improve eye-preservation rate for large tumors, other strategies should be considered for disease control.
Citations
Citations to this article as recorded by
Incidence, risk factors and outcomes of cataract surgery after plaque brachytherapy for posterior uveal melanoma Viktor T. Gill, Gustav Stålhammar Heliyon.2024; 10(1): e23447. CrossRef
Brachytherapy With 15- Versus 20-mm Ruthenium 106 Plaques Without Verification of Plaque Position Is Associated With Local Tumor Recurrence and Death in Posterior Uveal Melanoma Gustav Stålhammar International Journal of Radiation Oncology*Biology*Physics.2023; 117(5): 1125. CrossRef
The Role of Ruthenium Compounds in Neurologic Diseases: A Minireview Fátima Virgínia Gama Justi, Gabriella Araújo Matos, Juan de Sá Roriz Caminha, Cássia Rodrigues Roque, Edinilton Muniz Carvalho, Márcio Wilker Soares Campelo, Ludmila Belayev, Luiz Gonzaga de França Lopes, Reinaldo Barreto Oriá The Journal of Pharmacology and Experimental Therapeutics.2022; 380(1): 47. CrossRef
Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy Gilda Cennamo, Daniela Montorio, Luca D’ Andrea, Antonio Farella, Elide Matano, Mario Giuliano, Raffaele Liuzzi, Maria Angelica Breve, Sabino De Placido, Giovanni Cennamo Frontiers in Oncology.2022;[Epub] CrossRef
Uveal Melanoma: A Review of the Literature and Personal Experiences Yong Joon Kim, Christopher Seungkyu Lee, Sung Chul Lee Journal of Retina.2021; 6(2): 65. CrossRef
Prognostic Factors and Decision Tree for Long-Term Survival in Metastatic Uveal Melanoma Daniel Lorenzo, María Ochoa, Josep Maria Piulats, Cristina Gutiérrez, Luis Arias, Jaume Català, María Grau, Judith Peñafiel, Estefanía Cobos, Pere Garcia-Bru, Marcos Javier Rubio, Noel Padrón-Pérez, Bruno Dias, Joan Pera, Josep Maria Caminal Cancer Research and Treatment.2018; 50(4): 1130. CrossRef